Rechercher dans la communauté

Does anyone have any insight in the condo hotel market? Is it a good investment in Montreal? Toronto has so much offering (Thompson, King West, etc) and Montreal seems lagging (Crystal, Zero 1). I'm wondering if this is a profitable venture.

Out of History - A pace setting venture - Port Royal Condo Montreal 1965

À l'Exception de quelques geeks et financiers, peut de gens ici connaissent le concept du Bitcoin (Monnaie web open-source, sans banque, sans gouvernement attaché), même les médias traditionnels n'en parle pas du tout, pourtant, Montréal semble vouloir devenir une mini capitale de cet argent virtuel, selon un forum important du sujet. Source: Bitcointalk We are excited about the interest building around the establishment of the Bitcoin Embassy in Montreal and we have been working hard, putting together a team and organizing as we prepare to officially open our doors. The Bitcoin Embassy will serve as a hub where everything Bitcoin related will be given the opportunity to have it’s place under the same roof. We have in mind ; a bitcoin store / museum, a place for meet-ups, conferences, educational sessions, startup / venture capital center, everything that can help grow and promote Bitcoin throughout the Montreal community. Our goal is to make this city an international location for existing Bitcoin enthusiasts and future adopters alike. Join us at our next meet-up planned for Saturday, August 17th, 2013 at 2:30pm at the Bitcoin Embassy offices located at: 3485 St-Laurent Boul. Montreal. We look forward to discuss, plan and get people involved in the next phases of this exciting new project! Please get in touch with us at info@BitcoinEmbassy.ca Qui "Donne" un espace dans un endroit important comme St-Laurent? Beaucoup de commentaire sur Reddit /r/Montreal sur les connexions malveillantes du projet

http://www.theatlanticcities.com/jobs-and-economy/2013/06/new-global-start-cities/5144/ RICHARD FLORIDA Author's note: Start-up companies are a driving force in high-tech innovation and economic growth. Venture capital-backed companies like Intel, Apple, Genentech, Facebook, Google, and Twitter have powered the rise of whole new industries and shaped the way we live and work. Silicon Valley has long been the world's center for high-tech start-ups. Over the next few weeks, I'll be looking at the new geography of venture capital and high-tech start-ups and the rise of new start-up cities in the United States. I'll be also track to what degree start-up communities are shifting from their traditional locations in the suburbs to urban centers. America's start-up geography, with its well-established high-tech clusters in Silicon Valley and along Boston's Route 128, as well as more recent concentrations in urban centers like San Francisco and lower Manhattan, has been much discussed. But what does the world's start-up geography look like? What are the major start-up cities across the globe? Up until now, good data on the geography of start-ups outside the United States has been very hard, if not impossible, to come by. That's why a relatively new ranking of start-up cities across the globe by SeedTable is so interesting. SeedTable is a discovery platform that's built on the open-source database of more than 100,000 technology companies, investors, and entrepreneurs available at CrunchBase (one of the TechCrunch publications). SeedTable has information on more than 42,500 companies founded since 2002, including whether the companies are angel- or venture capital-funded (angel funders invest their own money; venture capitalists raise money from others), and whether the funder has exited, either by IPO or acquisition. The data cover 150 cities worldwide. It is reported by separate city or municipality, so the Martin Prosperity Institute's Zara Matheson organized the data by metro area and then mapped it by three major categories: global start-ups, companies receiving angel funding, and companies receiving institutional venture capital. The first map tracks start-ups across the cities of the world. New York tops the list with 144, besting San Francisco's 135. London is next with 90, followed by San Jose-Sunnyvale-Santa Clara (Silicon Valley) with 66, and Los Angeles with 64. Toronto and Boston-Cambridge tied for sixth with 34 each, Chicago is eighth with 31, Berlin ninth with 27, and Bangalore 10th with 26. Austin (23), Seattle (22), and São Paulo (21) each have more than 20 start-ups. Another 20 cities are home to 10 or more start-ups: Istanbul with 19; Vancouver and Moscow each with 17; New Delhi (15); Paris, and Atlanta with 14 each; Washington, D.C., Amsterdam, and Miami with 12 each; San Diego, Madrid, Singapore, and Sydney with 11 apiece; and Barcelona, Dublin, Tel Aviv, Dallas-Fort Worth, Mumbai, Buenos Aires and Rio de Janeiro, with 10 start-ups each. The second map charts the leading locations for companies receiving angel funding. Angel funding comes typically from wealthy individuals, often established entrepreneurs who invest their own personal funds in start-up companies. San Francisco now tops the list with 138 companies receiving angel funding, followed by New York with 117. London is again third with 62. San Jose is fourth with 60, Boston-Cambridge fifth with 50 and L.A. sixth with 48. Chicago and Philadelphia are tied for seventh with 19, and Seattle and Portland tied for 10th with 18 apiece. Nine more cities have 10 or more companies receiving angel funding: Toronto (17), D.C. (14), Berlin, and Paris (13 each), Atlanta, Barcelona and Boulder (12 each), Dublin (11), and Cincinnati (10). The third map above charts the locations of companies that attracted venture capital funding. Now the ranking changes considerably. San Francisco tops the list with 354, followed by Boston-Cambridge with 248, and San Jose with 216. New York is fourth with 160 and London fifth with 73. L.A. is sixth with 65, Seattle seventh with 57, San Diego eighth with 48, Austin ninth with 47, and Chicago 10th with 29. There are seven additional cities with 20 or more venture capital backed companies: Berlin (25), Toronto and Boulder (22 each), D.C., Paris, and Atlanta (21 each), and Denver with 20. The big takeaways? For one, these maps speak to the urban shift in the underlying model for high-technology start-ups. With its high-tech companies clustered in office parks along highway interchanges, Silicon Valley is the classic suburban nerdistan. But, at least according to these data, it appears to have been eclipsed by three more-urbanized areas. New York and London, admittedly much larger cities, both top it on start-up activity and the number of angel-funded companies, while the center of gravity for high-tech in the Bay Area has shifted somewhat from the valley to its more-urban neighbor San Francisco, which tops it in start-up activity, angel-funded, and venture capital-backed companies. The globalization of start-ups is the second big takeaway. American cities and metros — like Boston-Cambridge, L.A., Seattle, San Diego, Washington, D.C., Chicago, and Austin, as well as New York and San Francisco — all do very well. But London now ranks in the very top tier of start-up cities, while Toronto and Vancouver in Canada; Berlin (so much for the argument that Berlin is a lagging bohemian center with hardly any tech or entrepreneurial future), Paris, Amsterdam, Dublin, Madrid, and Barcelona in Europe; Bangalore, New Delhi, and Mumbai in India; Singapore and Sydney in the Asia Pacific region; and Buenos Aires and Rio de Janeiro in South America each have significant clusters of start-up activity. The world, as I have written, is spiky, with its most intensive economic activity concentrated in a relative handful of places. Global tech is no exception — and it is taking a decidedly urban turn. All maps by the Martin Prosperity Institute's Zara Matheson; Map data via Seedtable Keywords: London, New York, San Francisco, Maps, Start-Up, Venture Capital, Cities Richard Florida is Co-Founder and Editor at Large at The Atlantic Cities. He's also a Senior Editor at The Atlantic, Director of the Martin Prosperity Institute at the University of Toronto's Rotman School of Management, and Global Research Professor at New York University. He is a frequent speaker to communities, business and professional organizations, and founder of the Creative Class Group, whose current client list can be found here.

À la fois imposant et gracieux, le complexe résidentiel du 333 Sherbrooke constitue un exemple d’intégration urbaine. Érigé sur le terrain en friche de l’ancien couvent Saint-Louis-de-Gonzague, l’ensemble immobilier définit un nouveau lieu mariant harmonieusement architecture, design urbain et architecture du paysage. Le projet relie deux tours d’habitation de 10 étages s’élevant sur la rue Sherbrooke à de nouveaux condoplex de 4 étages jouxtant le square Saint-Louis, haut lieu de l’élite canadienne-française du début du siècle. La façade est rythmée par la répétition d’une baie type parfois agrémentée de balcons français qui donnent du relief à la paroi des bâtiments sur la rue Sherbrooke. La modulation de la volumétrie crée de nombreuses terrasses en cascades. Au sommet des immeubles, une structure en forme de pont suspendu fait office de trait-d’union et abrite une piscine extérieur de même qu’un toit terrasse jouissant de vues imprenables. Du côté jardin, une succession de petits bâtiments individuels de quatre étages s’articule autour d’une placette. Cette organisation s’associe facilement à l’environnement domestique typique du Quartier latin. CANADIAN COMMERCIAL REAL ESTATE NEWSLETTER Vol. 10 No. 50 Dec. 15, 2006 Editor: Maurice Gatien LL.B. HOMBURG JV INVESTS IN MONTREAL CONDO PROJECT HOMBURG BPF CANADA, a joint venture between Halifax-based Homburg Invest Inc. and SNS Property Finance (formerly Bouwfonds Property Finance) of The Netherlands, purchased a 66.67% interest in a condominium development in Montreal. The remaining 33.33% interest will be held by LES INVESTISSEMENTS F.P. S.E.C., whose general partner is Montreal-based TELEMEDIA DEVELOPMENT I INC. The joint venture has invested $3.8 million in the residential condominium development located at 333 Sherbrooke Street East in downtown Montreal. Phase I of the development currently includes an inventory of 35 completed units available for sale in a 9-storey condominium tower and 4 multiplexes (113 residential units in total). Phase II is yet to be constructed but will include 112 condominium units and 213 parking stalls housed in another nine story tower and another two multiplexes. Construction on Phase II is expected to begin early in the New Year. Link: http://www.homburginvest.com

(Courtesy of The Globe and Mail)

Wanted: biotech plan By DAVID CRANE, FreelanceFebruary 19, 2009 Sector in peril. New financing schemes are needed to maintain health of industry vital to Quebec's future New financing schemes are needed to maintain health of biotechnology industry vital to Quebec's future New financing schemes are needed to maintain health of biotechnology industry vital to Quebec's future Photograph by: Chris Schwarz, From Gazette Files Montreal has big ambitions to become a major biomedical centre in North America. The hope is that this will lead to jobs and wealth creation, just as promoting the aerospace industry has done. And it could. There's an obvious reason why. The world is on the verge of a biomedical revolution that will be a source of good jobs and prosperity for those societies that succeed in developing and commercializing the new knowledge. If the 20th century was known for great advances in the physical sciences and engineering, giving us the information and communication technology revolution, the 21st century could very well be the century of the biological revolution. But with all the new knowledge flowing out of universities and research hospitals, there's a huge problem - how to finance the growth of young startups commercializing this new knowledge into viable companies with a steady flow of revenues and profits. Montreal, for example, has dozens of such companies - like Theratechnologies, ConjuChem Biotechnologies, ProMetic Life Sciences, Enobia Pharma, Akela Pharma, Thallion Pharmaceuticals, Haemacure Corp., CryoCath Technologies, Paladin Labs, Ambrilia BioPhage Pharma, MethylGene, Alethia Biotherapeutics, Supratek Pharma, AngioChem and many more. Quite a few have products either now reaching the market or close to commercialization, or have promising projects in the clinical testing pipeline. But they must be able to attract the financing they need to keep on the road to potential success. In Canada today, the biotech industry is at a crucial point. Venture capital funding is drying up and many companies are running out of cash. Promising young companies may have to delay development of promising compounds. Or they could be forced to sell to bigger, usually foreign, players at bargain- basement prices. According to Thomson Reuters, which tracks venture investing in Canada, Montreal-area life-science companies raised only $69.9 million in venture capital last year, compared with $219.4 million in 2007. This year could be even more difficult. According to the Canadian Venture Capital and Private Equity Association, only $1.2 billion in new money for investment by venture firms in all high-tech sectors was raised last year, the lowest level on record since the mid-1990s. This is why we urgently need new financing mechanisms to sustain and grow our own life science companies. This should include a capacity to bring about mergers between young Canadian companies where complementarities exist. The industry had hoped the recent federal budget would help address their problems, but advocacy by groups such as BIOTECanada and the Canadian Venture and Private Equity Association were ignored by the Harper government. BIOTECanada had sought several initiatives. These included a one-time redemption for unused tax losses, limited to the lesser of $20 million or twice a company's annual R&D spending, and an exemption from capital-gains taxes in 2009 and 2010 for investors making new direct investments. Both measures would have required companies to reinvest in Canada. The venture-capital industry had sought creation of a $300-million fund of funds to invest in young companies and changes to the R&D tax incentive. British and U.S. biotech companies are facing many of the same challenges. In Britain, some 20 industry and academic leaders have urged the government to set up a $1.8-billion biotech fund, with half coming from government and half from the private sector. The group also wants a separate $900-million fund to make equity investments of $85 million to $170 million to help a small number of companies become more significant companies. British Prime Minister Gordon Brown has established a task force to follow up on this. The biotech industry is especially hard to finance. Not only are the human body, and disease, quite complex. But biotech development cycles are long and costly - projects can take up to 20 years to become successful and cost between $200 million to $300 million, or more, to bring to market. Few compounds succeed. All of these factors make R&D financing a challenge. But the goal to improve human health is important and the economic rewards can be high. This, though, depends on finding a better financing model if either of these is to be realized in Montreal or elsewhere. David Crane is a Toronto-based writer on innovation and globalization issues. He can be reached at crane@interlog.com © Copyright © The Montreal Gazette

Oct 10, 2007 9:28:00 AM MST Ineos Nova to shut down Montreal polystyrene plant by end of year (Nova-Chemicals) JOLIET, Ill. _ Ineos Nova, a joint venture between Nova Chemicals Corp. (TSX:NCX) and global petrochemicals giant Ineos, will shut down a Montreal polystyrene production facility by the end of the year. The closure will cut six per cent of the joint venture‘s polystyrene production and is part of a restructuring that aims to achieve about $50 million in annual synergies. It was not immediately known how many jobs, if any, are affected by the closure. “Shutting down the Montreal site will remove high-cost capacity and enable us to consolidate production at our most efficient manufacturing sites,‘‘ Kevin McQuade. “We are committed to providing our customers with an effective transition during the coming months.‘‘ In March, Nova announced the deal with global chemicals giant Ineos to expand the two companies‘ existing European styrene joint venture to include North American styrene and polystyrene plants in Canada and the United States. Styrene and polystyrene are widely produced petrochemicals used in making coffee cups, egg cartons, foam meat trays, toys and many other products. The joint venture company is expected to have revenues of about US$3.5 billion a year and will be the world‘s biggest producer of styrene and polystyrene _ widely produced petrochemicals used in making coffee cups, egg cartons, foam meat trays, toys and many other products. Nova keeps full ownership of its other major divisions, which make olefins and polyolefins, chemicals used in packaging, electronics, aviation, manufacturing and other sectors, and expandable polystyrene.